ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 312 filers reported holding ROYALTY PHARMA PLC in Q3 2023. The put-call ratio across all filers is 0.16 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,526,517 | -13.3% | 93,092 | -1.9% | 0.01% | -7.7% |
| Q2 2023 | $2,915,750 | -5.7% | 94,852 | +10.5% | 0.01% | -18.8% |
| Q1 2023 | $3,093,248 | -2.0% | 85,852 | +7.5% | 0.02% | -11.1% |
| Q4 2022 | $3,155,632 | -0.4% | 79,849 | +1.3% | 0.02% | -10.0% |
| Q3 2022 | $3,168,000 | +2.1% | 78,839 | +6.8% | 0.02% | +5.3% |
| Q2 2022 | $3,104,000 | +15.7% | 73,839 | +7.3% | 0.02% | +26.7% |
| Q1 2022 | $2,682,000 | -1.0% | 68,839 | +1.2% | 0.02% | +7.1% |
| Q4 2021 | $2,710,000 | +140.2% | 68,009 | +118.0% | 0.01% | +133.3% |
| Q3 2021 | $1,128,000 | -64.4% | 31,199 | -59.6% | 0.01% | -66.7% |
| Q2 2021 | $3,168,000 | -49.3% | 77,299 | -46.0% | 0.02% | -55.0% |
| Q1 2021 | $6,249,000 | -5.5% | 143,260 | +8.4% | 0.04% | -11.1% |
| Q4 2020 | $6,616,000 | +54.8% | 132,200 | +30.1% | 0.04% | +36.4% |
| Q3 2020 | $4,275,000 | – | 101,600 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $338,436,000 | 92.73% |
| Vantage Consulting Group Inc | 21,477,282 | $1,074,938,000 | 87.53% |
| Memorial Sloan Kettering Cancer Center | 3,565,887 | $178,473,000 | 75.56% |
| HARVARD MANAGEMENT CO INC | 14,690,780 | $735,274,000 | 39.88% |
| ROBERT WOOD JOHNSON FOUNDATION | 3,958,498 | $1,981,228,000 | 21.69% |
| Brown University | 381,759 | $19,107,000 | 13.82% |
| Overbrook Management Corp | 778,511 | $38,964,000 | 9.50% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 38,714,280 | $1,937,650,000 | 4.22% |
| Lagoda Investment Management, L.P. | 96,885 | $4,849,000 | 2.61% |
| HealthCor Management, L.P. | 1,339,530 | $67,043,000 | 2.58% |